Can a common drug stop Chemo's nerve pain?

NCT ID NCT03722680

Terminated Prevention Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether riluzole, a drug used for ALS, can prevent nerve damage caused by oxaliplatin chemotherapy in people with stage II/III colorectal cancer. About 80 participants will receive either riluzole or a placebo during their chemo. The study is currently suspended, so results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: riluzole
What this could lead to: If it works, this could point toward a way to prevent nerve damage from oxaliplatin chemotherapy, helping patients avoid pain and numbness.
What could go wrong: This is a small, early-phase trial that is currently suspended, so results may not be reliable. The drug may not prevent nerve damage or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm chemotherapy-induced neuropathy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OXALIPLATIN-INDUCED PERIPHERAL NEUROPATHY

Contacts and locations

Locations

CH Annecy-Genevois

Pringy, France
CH Beauvais

Beauvais, France
CHU de Clermont -Ferrand

Clermont-Ferrand, France
CHU de Dijon

Dijon, France
CHU de Reims

Reims, France
CHU de Saint-Etienne

Saint-Priest, France
Centre François Baclesse

Caen, France
Centre Georges François Leclerc

Dijon, France
Clinique St Côme

Compiègne, France
GHPSO

Creil, France
Hia Begin

Saint-Mandé, France
Hia Percy

Clamart, France
Hôpital Foch

Suresnes, France
ICO - Site Paul Papin

Angers, France
ICO - Site René Gauducheau

Saint-Herblain, France
Institut Jean Godinot

Reims, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.